1. Home
  2. GBIO vs RGC Comparison

GBIO vs RGC Comparison

Compare GBIO & RGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBIO
  • RGC
  • Stock Information
  • Founded
  • GBIO 2016
  • RGC 2014
  • Country
  • GBIO United States
  • RGC Hong Kong
  • Employees
  • GBIO N/A
  • RGC N/A
  • Industry
  • GBIO Biotechnology: Pharmaceutical Preparations
  • RGC Medicinal Chemicals and Botanical Products
  • Sector
  • GBIO Health Care
  • RGC Health Care
  • Exchange
  • GBIO Nasdaq
  • RGC Nasdaq
  • Market Cap
  • GBIO 64.8M
  • RGC 105.3M
  • IPO Year
  • GBIO 2020
  • RGC 2021
  • Fundamental
  • Price
  • GBIO $0.88
  • RGC $4.86
  • Analyst Decision
  • GBIO Strong Buy
  • RGC
  • Analyst Count
  • GBIO 2
  • RGC 0
  • Target Price
  • GBIO $6.50
  • RGC N/A
  • AVG Volume (30 Days)
  • GBIO 581.0K
  • RGC 8.8K
  • Earning Date
  • GBIO 03-05-2025
  • RGC 10-25-2024
  • Dividend Yield
  • GBIO N/A
  • RGC N/A
  • EPS Growth
  • GBIO N/A
  • RGC N/A
  • EPS
  • GBIO N/A
  • RGC N/A
  • Revenue
  • GBIO $18,582,000.00
  • RGC N/A
  • Revenue This Year
  • GBIO $212.74
  • RGC N/A
  • Revenue Next Year
  • GBIO N/A
  • RGC N/A
  • P/E Ratio
  • GBIO N/A
  • RGC N/A
  • Revenue Growth
  • GBIO 514.08
  • RGC N/A
  • 52 Week Low
  • GBIO $0.75
  • RGC $3.03
  • 52 Week High
  • GBIO $4.65
  • RGC $32.44
  • Technical
  • Relative Strength Index (RSI)
  • GBIO 28.66
  • RGC 44.96
  • Support Level
  • GBIO $0.85
  • RGC $4.75
  • Resistance Level
  • GBIO $1.01
  • RGC $5.21
  • Average True Range (ATR)
  • GBIO 0.12
  • RGC 0.30
  • MACD
  • GBIO 0.00
  • RGC 0.04
  • Stochastic Oscillator
  • GBIO 7.50
  • RGC 23.87

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About RGC Regencell Bioscience Holdings Limited

Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.

Share on Social Networks: